CoChat

The DOI matches its Crossref record; 80 of the 86 references it cites were found in a registry or an index; 22 of the 33 sources its claims cite were checked for support.

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition

Open access

Abstract

Direct targeting of the KRAS-G12C –mutant protein using covalent inhibitors (G12Ci) acts on human non–small cell lung cancer (NSCLC). However, drug resistance is an emerging concern in this approach. Here, we show that MRTX849, a covalent inhibitor targeting the KRAS-G12C mutation, leads to the reactivation of the mitogen-activated protein kinase signaling pathway in MRTX849-resistant NSCLC and pancreatic ductal adenocarcinoma. A genome-wide CRISPR screen revealed that the adenosine triphosphate binding cassette transporter ABCC1 mediates MRTX849 resistance. Functional studies demonstrated that the transcription factor JUN drives ABCC1 expression, resulting in multidrug resistance. An unbiased drug screen identified the tyrosine kinase inhibitor dasatinib that potentiates MRTX849 efficacy by inhibiting SRC-dependent JUN activation, avoiding multidrug resistance and tumor suppression in vitro as well as in suitable preclinical mouse models and patient-derived organoids. SRC inhibitors (DGY-06-116, dasatinib, and bosutinib) also exhibit synergistic effects with MRTX849 in eliminating various tumor cell lines carrying KRAS-G12C mutations. Thus, SRC inhibitors amplify the therapeutic utility of G12Ci.

Overview

CoChat Summary

TL;DR

MRTX849 resistance in KRAS-G12C NSCLC and PDAC reactivates MAPK signaling and up-regulates ABCC1 through SRC-JUN, producing multidrug resistance. SRC inhibitors such as dasatinib, bosutinib, and DGY-06-116 synergize with MRTX849 in resistant cell lines, mouse models, and patient-derived organoids.

Key findings

  • MRTX849-resistant MIA PaCa-2R and Calu1R cells had higher MRTX849 IC50 values than parental cells (MIA PaCa-2R = 60.2 μM versus MIA PaCa-2 = 0.13 μM; Calu1R = 19.2 μM versus Calu1 = 2.5 μM), with ERK/MAPK reactivation and reduced intracellular MRTX849 accumulation.
  • ABCC1 mediated resistance: ABCC1 knockout or the ABCC1 inhibitor MK-571 sensitized resistant cells to MRTX849, ABCC1 overexpression induced resistance, and ABCC1 up-regulation also conferred gemcitabine resistance.
  • JUN drove ABCC1 expression: JUN bound the ABCC1 promoter at positions −501 to −397 and the CCND1 promoter at −1073 to −893; JUN overexpression increased ABCC1 and reduced MRTX849 growth inhibition, while ABCC1 knockout abrogated JUN-induced resistance.
  • A screen of 1421 FDA-approved drugs identified 63 drugs targeting 19 kinases that restored MRTX849-mediated growth inhibition; dasatinib was prioritized and synergized with MRTX849 across 11 KRAS-G12C–mutant NSCLC cell lines but not in KRAS-G12D PANC1 or KRAS WT cells. SRC knockdown sensitized resistant cells to MRTX849, and SRC WT or SRC Y530F, but not kinase-dead SRC K298M, induced resistance.

Methods

  • MRTX849-resistant Calu1R and MIA PaCa-2R cells were generated by culturing KRAS-G12C–mutant Calu1 and MIA PaCa-2 cells with increasing MRTX849 (100 nM–50,000 nM) for 6 months and maintaining them at 1000 nM; analyses included RNA-seq, CRISPR-Cas9 screen reanalysis, phosphokinase arrays, ChIP, immunoblots, CCK-8, colony formation, LC-MS/MS, RAS-GTP pull-down, and molecular docking.
  • Drug screening used 1421 FDA-approved drugs at 10 μM with or without MRTX849 (1 μM) in MIA PaCa-2 and MIA PaCa-2R cells, with synergy assessed by SynergyFinder; validation included KRAS-G12C NSCLC lines, KRAS-G12D PANC1, KRAS WT cells, and patient-derived organoids HCC4300-PDX-ORG and HCC4285-PDX-ORG.
  • In vivo studies used subcutaneous MIA PaCa-2/MIA PaCa-2R or Calu1/Calu1R xenografts in nude mice and mKRC.1 syngeneic C57BL/6 mice, treated with MRTX849 alone or combined with dasatinib or bosutinib, with tumor growth, survival, immunohistochemistry, body weight, and organ weights assessed.

Limitations

  • The paper states that ABCC1 knockout only partially reversed resistance in MIA PaCa-2R cells, indicating additional resistance mechanisms, and that ABCC1 up-regulation is likely not the sole mechanism of acquired KRAS-G12Ci resistance.
  • The paper notes that direct pharmacological inhibition of JUN remains challenging, small-molecule ABCC1 inhibition has failed in clinical trials, and SRC inhibitors are associated with adverse events including bleeding, infection, anemia, thrombocytopenia, diarrhea, edema, pleural effusion, and pulmonary hypertension; bosutinib plus MRTX849 decreased spleen, pancreas, heart, and kidney weights and caused kidney and pancreas histopathology in mice.
  • Evident from the text: the findings are preclinical, based on two main resistant cell line models, mouse xenografts/syngeneic models, and organoids, with no clinical validation; resistance mechanisms differed between AMG510 and MRTX849 in some contexts, and gemcitabine plus dasatinib showed toxicity without a significant tumor weight difference versus gemcitabine alone.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/sciadv.adq4274

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Reactivation of the MAPK signaling pathway in MRTX849-resistant KRAS-G12C–mutant cells. (A) Calu1 and its KRAS-G12Ci–resistant cells (Calu1R) and MIA PaCa-2 and its resistant cells (MIA PaCa-2R) were treated with MRTX849 at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assay (n = 3 biologically independent samples; ***P < 0.001; two-way ANOVA; data are presented as means ± SD). (B to D) Cell clonogenic assay. The cells were treated with MRTX849 (5 μM) for 24 hours and observed for 7 to 14 days. The cell colonies were stained with 0.1% crystal violet for evaluation. Quantification was performed by ImageJ (n = 3 biologically independent samples; **P < 0.01; Student’s t test; data are presented as means ± SD). (E) Number of differentially expressed genes identified by iDEP96 using an FDR cutoff of 0.1 and a minimum fold change of 2 between the indicated groups. (F) KEGG pathway analysis of differentially down-regulated genes in MIA PaCa-2 cells treated with MRTX849 compared to the control. (G) KEGG pathway analysis of differentially down-regulated genes in MIA PaCa-2–resistant cells (MIA PaCa-2R) treated with MRTX849 compared to the control. (H) KEGG pathway analysis of differentially up-regulated genes in MIA PaCa-2–resistant cells (MIA PaCa-2R) compared to MIA PaCa-2 cells. (I) GSEA showing that the MAPK signaling pathway was statistically up-regulated between MIA PaCa-2R and MIA PaCa-2 cells (nominal P value of <0.01). (J) Immunoblot analysis of the indicated proteins of cells treated with 1 μM MRTX849 at the indicated time. The blots shown are representative of three repeats. h, hours; KEGG, Kyoto Encyclopedia of Genes and Genomes; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Fig. 1. Reactivation of the MAPK signaling pathway in MRTX849-resistant KRAS-G12C–mutant cells. (A) Calu1 and its KRAS-G12Ci–resistant cells (Calu1R) and MIA PaCa-2 and its resistant cells (MIA PaCa-2R) were treated with MRTX849 at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assay (n = 3 biologically independent samples; ***P < 0.001; two-way ANOVA; data are presented as means ± SD). (B to D) Cell clonogenic assay. The cells were treated with MRTX849 (5 μM) for 24 hours and observed for 7 to 14 days. The cell colonies were stained with 0.1% crystal violet for evaluation. Quantification was performed by ImageJ (n = 3 biologically independent samples; **P < 0.01; Student’s t test; data are presented as means ± SD). (E) Number of differentially expressed genes identified by iDEP96 using an FDR cutoff of 0.1 and a minimum fold change of 2 between the indicated groups. (F) KEGG pathway analysis of differentially down-regulated genes in MIA PaCa-2 cells treated with MRTX849 compared to the control. (G) KEGG pathway analysis of differentially down-regulated genes in MIA PaCa-2–resistant cells (MIA PaCa-2R) treated with MRTX849 compared to the control. (H) KEGG pathway analysis of differentially up-regulated genes in MIA PaCa-2–resistant cells (MIA PaCa-2R) compared to MIA PaCa-2 cells. (I) GSEA showing that the MAPK signaling pathway was statistically up-regulated between MIA PaCa-2R and MIA PaCa-2 cells (nominal P value of <0.01). (J) Immunoblot analysis of the indicated proteins of cells treated with 1 μM MRTX849 at the indicated time. The blots shown are representative of three repeats. h, hours; KEGG, Kyoto Encyclopedia of Genes and Genomes; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.CC BY · PubMed Central
Fig. 2. ABCC1 confers resistance in MRTX849-resistant cells. (A) GO enrichment of RNA-seq analysis. (B) GSEA was performed using a clinical tissue sample from an AMG510-resistant patient, available in a published database. A filtering step was applied to select gene sets associated with plasma membrane functions. (C) Heatmap showing the expression of ABC transporters in cells treated with MRTX849 (4 hours, 1 μM), based on RNA-seq. (D and E) Expression of ABCC1 and ABCG2 was examined by immunoblot analyses. Quantification was performed by the Image Lab software. (F) Partial volcano plot of 45 ABC transporters analyzed from genome-wide CRISPR-Cas9 screening. The x axis represents log2 fold changes of each gene. The y axis represents the negative logarithm of the P value. (G to I) MIA PaCa-2R or Calu1R and their ABCC1 knockout (KO) cells were treated with MRTX849 followed by CCK-8 assays. (J and K) Small interfering RNA targeting ABCB1, ABCC3, ABCG1, and ABCG2 was used for gene knockdown, followed by MRTX849 treatment and cell viability assays. The gene expressions in MIA PaCa-2R cells were measured by quantitative PCR (Student’s t test). (L) Cells were treated with the ABCC1 inhibitor MK-571 and MRTX849 for 3 days, followed by CCK-8 assays. (M) Cells were transfected with an empty vector or ABCC1, treated with MRTX849 for 3 days, and subjected to CCK-8 assays. (N) Cells were treated with 1 μM MRTX849 for 6 hours or with 10 μM MK-571 for 24 hours, followed by 1 μM MRTX849 for 6 hours. Intracellular MRTX849 accumulation was quantified using LC-MS/MS (Student’s t test). The blots shown are representative of three independent experiments. Statistical analysis was performed using two-way ANOVA unless otherwise noted (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Data are presented as means ± SD, with n = 3 biologically independent samples.
Fig. 2. ABCC1 confers resistance in MRTX849-resistant cells. (A) GO enrichment of RNA-seq analysis. (B) GSEA was performed using a clinical tissue sample from an AMG510-resistant patient, available in a published database. A filtering step was applied to select gene sets associated with plasma membrane functions. (C) Heatmap showing the expression of ABC transporters in cells treated with MRTX849 (4 hours, 1 μM), based on RNA-seq. (D and E) Expression of ABCC1 and ABCG2 was examined by immunoblot analyses. Quantification was performed by the Image Lab software. (F) Partial volcano plot of 45 ABC transporters analyzed from genome-wide CRISPR-Cas9 screening. The x axis represents log2 fold changes of each gene. The y axis represents the negative logarithm of the P value. (G to I) MIA PaCa-2R or Calu1R and their ABCC1 knockout (KO) cells were treated with MRTX849 followed by CCK-8 assays. (J and K) Small interfering RNA targeting ABCB1, ABCC3, ABCG1, and ABCG2 was used for gene knockdown, followed by MRTX849 treatment and cell viability assays. The gene expressions in MIA PaCa-2R cells were measured by quantitative PCR (Student’s t test). (L) Cells were treated with the ABCC1 inhibitor MK-571 and MRTX849 for 3 days, followed by CCK-8 assays. (M) Cells were transfected with an empty vector or ABCC1, treated with MRTX849 for 3 days, and subjected to CCK-8 assays. (N) Cells were treated with 1 μM MRTX849 for 6 hours or with 10 μM MK-571 for 24 hours, followed by 1 μM MRTX849 for 6 hours. Intracellular MRTX849 accumulation was quantified using LC-MS/MS (Student’s t test). The blots shown are representative of three independent experiments. Statistical analysis was performed using two-way ANOVA unless otherwise noted (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Data are presented as means ± SD, with n = 3 biologically independent samples.CC BY · PubMed Central
Fig. 3. JUN positively regulates MRTX849-induced ABCC1 expression. (A) Heatmap of the phosphorylation of kinases in MIA PaCa-2 and MIA PaCa-2R by human phosphokinase array. (B and C) GO terms of gene enrichment in the MF (B) and CC (C) categories of the 246 differentially KRAS-G12Ci resistance-associated genes from an analysis of a CRISPR screening. CC, cellular component; MF, molecular function. (D) Heatmap of the expression pattern of 25 transcription factors in MIA PaCa-2 and MIA PaCa-2R in response to MRTX849 by next-generation sequencing. (E) Immunoprecipitation (IP) assay with anti-JUN antibodies using chromatin fraction in MIA PaCa-2 and MIA PaCa-2R cells. (F) The ABCC promoter region is divided into a, b, c, and d fractions. ChIP assays were performed using digested chromatin from Calu1/Calu1R, MIA PaCa-2/MIA PaCa-2R, and anti-JUN antibodies. The binding DNA was purified. The ABCC1 promoter fractions a to d were measured by quantitative real-time PCR. TSS, Transcription Start Site. (G) Immunoblots of the indicated protein levels in MIA PaCa-2, MIA PaCa-2R, Calu1, and Calu1R cells. (H and I) MIA PaCa-2 and Calu1 cells were transfected with pCDH-Flag-JUN and vector plasmid for 24 hours and then treated with MRTX849 for 3 days. The expression of the indicated proteins was shown by Western blot analysis. Cell viability was assessed. (J) Calu1 cells were infected with lentivirus expressing WT JUN followed by CRISPR-Cas9–mediated ABCC1 knockout. The expression of ABCC1 and FLAG-JUN in Calu1 was measured by Western blot. Calu1 cells with JUN overexpression in the absence or presence of ABCC1 expression were exposed to the indicated drugs at the indicated concentrations for 72 hours, and cell viability was assessed. The blots shown are representative of three repeats. Statistical analysis was performed using two-way ANOVA (**P < 0.01; ****P < 0.0001). Data are presented as means ± SD, with n = 3 biologically independent samples.
Fig. 3. JUN positively regulates MRTX849-induced ABCC1 expression. (A) Heatmap of the phosphorylation of kinases in MIA PaCa-2 and MIA PaCa-2R by human phosphokinase array. (B and C) GO terms of gene enrichment in the MF (B) and CC (C) categories of the 246 differentially KRAS-G12Ci resistance-associated genes from an analysis of a CRISPR screening. CC, cellular component; MF, molecular function. (D) Heatmap of the expression pattern of 25 transcription factors in MIA PaCa-2 and MIA PaCa-2R in response to MRTX849 by next-generation sequencing. (E) Immunoprecipitation (IP) assay with anti-JUN antibodies using chromatin fraction in MIA PaCa-2 and MIA PaCa-2R cells. (F) The ABCC promoter region is divided into a, b, c, and d fractions. ChIP assays were performed using digested chromatin from Calu1/Calu1R, MIA PaCa-2/MIA PaCa-2R, and anti-JUN antibodies. The binding DNA was purified. The ABCC1 promoter fractions a to d were measured by quantitative real-time PCR. TSS, Transcription Start Site. (G) Immunoblots of the indicated protein levels in MIA PaCa-2, MIA PaCa-2R, Calu1, and Calu1R cells. (H and I) MIA PaCa-2 and Calu1 cells were transfected with pCDH-Flag-JUN and vector plasmid for 24 hours and then treated with MRTX849 for 3 days. The expression of the indicated proteins was shown by Western blot analysis. Cell viability was assessed. (J) Calu1 cells were infected with lentivirus expressing WT JUN followed by CRISPR-Cas9–mediated ABCC1 knockout. The expression of ABCC1 and FLAG-JUN in Calu1 was measured by Western blot. Calu1 cells with JUN overexpression in the absence or presence of ABCC1 expression were exposed to the indicated drugs at the indicated concentrations for 72 hours, and cell viability was assessed. The blots shown are representative of three repeats. Statistical analysis was performed using two-way ANOVA (**P < 0.01; ****P < 0.0001). Data are presented as means ± SD, with n = 3 biologically independent samples.CC BY · PubMed Central
Fig. 4. FDA-approved drug screen identifies that dasatinib inhibits JUN expression and enhances the efficacy of MRTX849. (A) Procedures of the US Food and Drug Administration (FDA)-approved drug screen. Pie chart of drugs with color codes corresponding to hit target type is shown. The calculating score is determined by taking log2 of the ratio of cell viability between drug-treated MIA PaCa-2 cells and drug-treated MIA PaCa-2R cells. (B) ZIP synergy score was calculated by SynergyFinder (43) between dasatinib/palbociclib and MRTX849. (C and D) MIA PaCa-2/Calu1 and MIA PaCa-2R/Calu1R cells were treated with MRTX849 and dasatinib for 3 days. Cell viability was measured by CCK-8 assay. (E) Cell clonogenic assay. MIA PaCa-2 and MIA PaCa-2R cells were treated with the MRTX849 (1 μM) and dasatinib for 24 hours. Calu1 and Calu1R cells were treated with the MRTX849 (10 μM) and dasatinib for 24 hours. All cells were observed for 10 days, followed by evaluation using crystal violet staining. Quantification was performed by ImageJ. (F) Heatmap showing the expression of the cyclin proteins in MIA PaCa-2 and MIA PaCa-2R in response to MRTX849 by next-generation sequencing. (G) Volcano plot of differential gene expression between MRTX849 and vehicle in MIA PaCa-2 (absolute fold change of ≥2; q value <0.05). CCND1 was substantially down-regulated. (H) GSEA showing that the JNK signaling pathway is up-regulated between MIA PaCa-2R and MIA PaCa-2 cells (nominal P value of <0.0001). (I) Immunoblot analysis of the indicated proteins of cells treated with 1 μM dasatinib and 1 μM MRTX849 for 24 hours. The blots shown are representative of three independent experiments. Statistical analysis was performed using two-way ANOVA unless otherwise noted (*P < 0.05; **P < 0.01; ***P < 0.001). Data are presented as means ± SD, with n = 3 biologically independent samples.
Fig. 4. FDA-approved drug screen identifies that dasatinib inhibits JUN expression and enhances the efficacy of MRTX849. (A) Procedures of the US Food and Drug Administration (FDA)-approved drug screen. Pie chart of drugs with color codes corresponding to hit target type is shown. The calculating score is determined by taking log2 of the ratio of cell viability between drug-treated MIA PaCa-2 cells and drug-treated MIA PaCa-2R cells. (B) ZIP synergy score was calculated by SynergyFinder (43) between dasatinib/palbociclib and MRTX849. (C and D) MIA PaCa-2/Calu1 and MIA PaCa-2R/Calu1R cells were treated with MRTX849 and dasatinib for 3 days. Cell viability was measured by CCK-8 assay. (E) Cell clonogenic assay. MIA PaCa-2 and MIA PaCa-2R cells were treated with the MRTX849 (1 μM) and dasatinib for 24 hours. Calu1 and Calu1R cells were treated with the MRTX849 (10 μM) and dasatinib for 24 hours. All cells were observed for 10 days, followed by evaluation using crystal violet staining. Quantification was performed by ImageJ. (F) Heatmap showing the expression of the cyclin proteins in MIA PaCa-2 and MIA PaCa-2R in response to MRTX849 by next-generation sequencing. (G) Volcano plot of differential gene expression between MRTX849 and vehicle in MIA PaCa-2 (absolute fold change of ≥2; q value <0.05). CCND1 was substantially down-regulated. (H) GSEA showing that the JNK signaling pathway is up-regulated between MIA PaCa-2R and MIA PaCa-2 cells (nominal P value of <0.0001). (I) Immunoblot analysis of the indicated proteins of cells treated with 1 μM dasatinib and 1 μM MRTX849 for 24 hours. The blots shown are representative of three independent experiments. Statistical analysis was performed using two-way ANOVA unless otherwise noted (*P < 0.05; **P < 0.01; ***P < 0.001). Data are presented as means ± SD, with n = 3 biologically independent samples.CC BY · PubMed Central
Fig. 5. SRC positively regulates MRTX849-induced multidrug resistance. (A) MIA PaCa-2 and MIA PaCa-2R cells were treated with dasatinib (1 μM, 24 hours) and MRTX849 (1 μM, 48 hours), followed by human phosphokinase array and quantification. (B) Cells were treated with 1 μM dasatinib and 1 μM MRTX849 for 24 hours, followed by RAS-GTP pull-down assays, Western blotting, and quantification. (C) Model of phosphorylated RAF1 bound to the SH2. (a) Structure of the computer-generated model: RAF1 (based on AlphaFold AF-P04049-F1) and SRC (based on the PDB). (b) SH2 (PDB: 1FMK) complexed with phosphorylated tyrosine pentapeptide Y341 (RAF1), interacting with Arg178 and Thr182 of SRC. (c) Human SH2 (PDB: 1HCS, dark gray) complexed with Y341 (yellow). (D) Immunoblot analysis of gene knockdown in Calu1R and MIA PaCa-2R cells. (E) Cells were treated with MRTX849 for 3 days and then assessed by CCK-8 assays. (F) Cells were transfected with an empty vector, SRC-WT, SRC-K298M (kinase dead), or SRC-Y530F (active form), treated with drugs for 3 days, and assessed by CCK-8 assays. (G) Cells were transfected with the indicated plasmids, treated with MRTX849 (1 μM) for 3 days and analyzed by immunoblotting. (H) HOP62 and H2030 cells were treated with MRTX849 (1 μM) for 1 and 7 days, followed by immunoblots. (I and J) ABCC1 WT and knockout cells of HOP62 and H2030 cells were transfected with an empty vector or SRC-WT-Flag and treated with MRTX849 for 3 days, followed by CCK-8 assays. The blots shown are representative of three independent experiments. Statistical analysis was performed using two-way ANOVA unless otherwise noted (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Data are presented as means ± SD, with n = 3 biologically independent samples.
Fig. 5. SRC positively regulates MRTX849-induced multidrug resistance. (A) MIA PaCa-2 and MIA PaCa-2R cells were treated with dasatinib (1 μM, 24 hours) and MRTX849 (1 μM, 48 hours), followed by human phosphokinase array and quantification. (B) Cells were treated with 1 μM dasatinib and 1 μM MRTX849 for 24 hours, followed by RAS-GTP pull-down assays, Western blotting, and quantification. (C) Model of phosphorylated RAF1 bound to the SH2. (a) Structure of the computer-generated model: RAF1 (based on AlphaFold AF-P04049-F1) and SRC (based on the PDB). (b) SH2 (PDB: 1FMK) complexed with phosphorylated tyrosine pentapeptide Y341 (RAF1), interacting with Arg178 and Thr182 of SRC. (c) Human SH2 (PDB: 1HCS, dark gray) complexed with Y341 (yellow). (D) Immunoblot analysis of gene knockdown in Calu1R and MIA PaCa-2R cells. (E) Cells were treated with MRTX849 for 3 days and then assessed by CCK-8 assays. (F) Cells were transfected with an empty vector, SRC-WT, SRC-K298M (kinase dead), or SRC-Y530F (active form), treated with drugs for 3 days, and assessed by CCK-8 assays. (G) Cells were transfected with the indicated plasmids, treated with MRTX849 (1 μM) for 3 days and analyzed by immunoblotting. (H) HOP62 and H2030 cells were treated with MRTX849 (1 μM) for 1 and 7 days, followed by immunoblots. (I and J) ABCC1 WT and knockout cells of HOP62 and H2030 cells were transfected with an empty vector or SRC-WT-Flag and treated with MRTX849 for 3 days, followed by CCK-8 assays. The blots shown are representative of three independent experiments. Statistical analysis was performed using two-way ANOVA unless otherwise noted (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Data are presented as means ± SD, with n = 3 biologically independent samples.CC BY · PubMed Central
Fig. 6. Synergistic effect of MRTX849 and dasatinib on tumor suppression in mouse models. (A) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (35 mg/kg, p.o., oral gavage) and dasatinib (35 mg/kg, oral gavage) in MIA PaCa-2/MIA PaCa-2R xenograft models. sc, subcutaneously. (B) The tumor growth was monitored twice per week (n = 8 to 10 tumor; **P < 0.01; ***P < 0.001, two-way ANOVA). (C and D) Body weight was monitored after the administration of MRTX849 and dasatinib in nude mice for the indicated weeks after MIA PaCa-2/MIA PaCa-2R inoculation. (E) Survival curve of each group [n = 5 mice per group; **P < 0.01 compared with the vehicle; ##P < 0.01 compared with MRTX849 treatment, log-rank (Mantel-Cox) test]. (F) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (25 mg/kg, p.o., twice a week for 6 weeks) and dasatinib (35 mg/kg, p.o., twice a week for 6 weeks) in Calu1/Calu1R xenograft models. (G) Tumor growth was monitored twice per week (n = 8 to 10 tumors). (H) Body weight was monitored after the administration of MRTX849 and dasatinib in nude mice for the indicated weeks after Calu1/Calu1R inoculation. (I) Survival curve of each group [n = 5 mice per group; *P < 0.05, log-rank (Mantel-Cox) test]. (J) Staining of ABCC1, p-ERK1/2, and PCNA in MIA PaCa-2/MIA PaCa-2R xenograft models on day 29. Scale bars, 50 μm. Quantification of immunohistochemistry analysis was performed by calculation using the immunoreactive score (79) (n = 3; *P < 0.05 or **P < 0.01 compared with the vehicle; ##P < 0.01 compared with MRTX849 treatment).
Fig. 6. Synergistic effect of MRTX849 and dasatinib on tumor suppression in mouse models. (A) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (35 mg/kg, p.o., oral gavage) and dasatinib (35 mg/kg, oral gavage) in MIA PaCa-2/MIA PaCa-2R xenograft models. sc, subcutaneously. (B) The tumor growth was monitored twice per week (n = 8 to 10 tumor; **P < 0.01; ***P < 0.001, two-way ANOVA). (C and D) Body weight was monitored after the administration of MRTX849 and dasatinib in nude mice for the indicated weeks after MIA PaCa-2/MIA PaCa-2R inoculation. (E) Survival curve of each group [n = 5 mice per group; **P < 0.01 compared with the vehicle; ##P < 0.01 compared with MRTX849 treatment, log-rank (Mantel-Cox) test]. (F) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (25 mg/kg, p.o., twice a week for 6 weeks) and dasatinib (35 mg/kg, p.o., twice a week for 6 weeks) in Calu1/Calu1R xenograft models. (G) Tumor growth was monitored twice per week (n = 8 to 10 tumors). (H) Body weight was monitored after the administration of MRTX849 and dasatinib in nude mice for the indicated weeks after Calu1/Calu1R inoculation. (I) Survival curve of each group [n = 5 mice per group; *P < 0.05, log-rank (Mantel-Cox) test]. (J) Staining of ABCC1, p-ERK1/2, and PCNA in MIA PaCa-2/MIA PaCa-2R xenograft models on day 29. Scale bars, 50 μm. Quantification of immunohistochemistry analysis was performed by calculation using the immunoreactive score (79) (n = 3; *P < 0.05 or **P < 0.01 compared with the vehicle; ##P < 0.01 compared with MRTX849 treatment).CC BY · PubMed Central
Fig. 7. Efficacy and safety profile of the combination of MRTX849 and bosutinib in a KRAS G12C murine model mKRC.1. (A) Bright-field microscopy images of 3D sphere cultures of MIA PaCa-2R and mKRC.1 with vehicles, MRTX849, dasatinib, DGY-06-116, and bosutinib as well as combinations, after 7 days of treatment. Scale bars, 500 μm. (B) Measurement of cell viability in 3D sphere cultures of MIA PaCa-2R and mKRC.1 with different treatments (n = 3 biologically independent samples; ****P < 0.0001, two-way ANOVA). (C) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (35 mg/kg, oral gavage, p.o.) and bosutinib (75 mg/kg, oral gavage) in mKRC.1 syngeneic mouse models. The tumor growth was monitored twice per week (n = 8 to 10 tumors; *P < 0.05; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey’s multiple comparisons test). (D) Photo of tumors on day 27. (E) Tumor weight on day 27. n = 8 tumor per group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, two-way ANOVA. (F) Body weight was monitored after the treatments for the indicated weeks. n = 5 mice per group; two-way ANOVA. (G) Organ weight in each group was measured on day 27 (n = 5; *P < 0.05; ***P < 0.001; ****P < 0.0001, two-way ANOVA). (H) Representative images of H&E staining of the liver, lung, pancreas, and spleen from mice bearing mKRC.1 tumors, treated with either vehicle or the combination of MRTX849 and bosutinib. Scale bars, 50 μm.
Fig. 7. Efficacy and safety profile of the combination of MRTX849 and bosutinib in a KRAS G12C murine model mKRC.1. (A) Bright-field microscopy images of 3D sphere cultures of MIA PaCa-2R and mKRC.1 with vehicles, MRTX849, dasatinib, DGY-06-116, and bosutinib as well as combinations, after 7 days of treatment. Scale bars, 500 μm. (B) Measurement of cell viability in 3D sphere cultures of MIA PaCa-2R and mKRC.1 with different treatments (n = 3 biologically independent samples; ****P < 0.0001, two-way ANOVA). (C) Schematic diagram of the therapeutic strategy of the combination of MRTX849 (35 mg/kg, oral gavage, p.o.) and bosutinib (75 mg/kg, oral gavage) in mKRC.1 syngeneic mouse models. The tumor growth was monitored twice per week (n = 8 to 10 tumors; *P < 0.05; ***P < 0.001; ****P < 0.0001, two-way ANOVA with Tukey’s multiple comparisons test). (D) Photo of tumors on day 27. (E) Tumor weight on day 27. n = 8 tumor per group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, two-way ANOVA. (F) Body weight was monitored after the treatments for the indicated weeks. n = 5 mice per group; two-way ANOVA. (G) Organ weight in each group was measured on day 27 (n = 5; *P < 0.05; ***P < 0.001; ****P < 0.0001, two-way ANOVA). (H) Representative images of H&E staining of the liver, lung, pancreas, and spleen from mice bearing mKRC.1 tumors, treated with either vehicle or the combination of MRTX849 and bosutinib. Scale bars, 50 μm.CC BY · PubMed Central
Fig. 8. ABCC1 up-regulation in MRTX849-resistant cells leads to gemcitabine resistance. (A) Calu1/Calu1R and MIA PaCa-2/MIA PaCa-2R cells were treated with gemcitabine for 4 days at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assays. (B) Calu1R and MIA PaCa-2R ABCC1 WT and knockout cells were treated with gemcitabine for 2 days at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assays. (C) Calu1 and MIA PaCa-2 cells were transfected with ABCC1 or vector and then treated with gemcitabine for 2 days at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assays. (D) Calu1 cells were infected with lentivirus expressing WT JUN followed by CRISPR-Cas9–mediated ABCC1 knockout. The cells were treated with gemcitabine for 2 days followed by CCK-8 cell viability assays. (E) Calu1R and MIA PaCa-2R cells were treated with gemcitabine in the presence or absence of dasatinib for 3 days followed by cell viability assays. (F) Schematic diagram of the therapeutic strategy of gemcitabine and dasatinib in MIA PaCa-2/MIA PaCa-2R xenograft models. The tumor growth was monitored twice per week (n = 5 mice). ip, intraperitoneally. (G) Photo of the tumors on day 42. (H) Tumor weight on day 42 (n = 5). (I) Body weight was monitored in nude mice for the indicated weeks after MIA PaCa-2/MIA PaCa-2R inoculation (n = 5). Statistical analysis was performed using two-way ANOVA (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). n = 3 biologically independent samples unless otherwise specified. n.s., not significant.
Fig. 8. ABCC1 up-regulation in MRTX849-resistant cells leads to gemcitabine resistance. (A) Calu1/Calu1R and MIA PaCa-2/MIA PaCa-2R cells were treated with gemcitabine for 4 days at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assays. (B) Calu1R and MIA PaCa-2R ABCC1 WT and knockout cells were treated with gemcitabine for 2 days at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assays. (C) Calu1 and MIA PaCa-2 cells were transfected with ABCC1 or vector and then treated with gemcitabine for 2 days at the indicated concentrations. The percentage of viable cells is shown relative to untreated controls by CCK-8 assays. (D) Calu1 cells were infected with lentivirus expressing WT JUN followed by CRISPR-Cas9–mediated ABCC1 knockout. The cells were treated with gemcitabine for 2 days followed by CCK-8 cell viability assays. (E) Calu1R and MIA PaCa-2R cells were treated with gemcitabine in the presence or absence of dasatinib for 3 days followed by cell viability assays. (F) Schematic diagram of the therapeutic strategy of gemcitabine and dasatinib in MIA PaCa-2/MIA PaCa-2R xenograft models. The tumor growth was monitored twice per week (n = 5 mice). ip, intraperitoneally. (G) Photo of the tumors on day 42. (H) Tumor weight on day 42 (n = 5). (I) Body weight was monitored in nude mice for the indicated weeks after MIA PaCa-2/MIA PaCa-2R inoculation (n = 5). Statistical analysis was performed using two-way ANOVA (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). n = 3 biologically independent samples unless otherwise specified. n.s., not significant.CC BY · PubMed Central
Fig. 9. Effects of MRTX849 and SRC inhibitors in the treatment of KRAS-G12C–mutant patient-derived organoids. (A) Patient-derived organoids HCC4300-PDX-ORG were treated with MRTX849 for 1 or 7 days, and the expression of the indicated proteins was measured. The blots shown are representative of three repeats. (B) Patient-derived organoids HCC4300-PDX-ORG treated with vehicle, MRTX849, dasatinib, or DGY-06-116, as well as combinations, after 7 days of treatment. Cell viability of the organoids was measured by CCK-8. (C) Bright-field microscopy images of HCC4300-PDX-ORG treated with vehicle, MRTX849, or bosutinib, as well as combinations, after 7 days of treatment. Scale bars, 50 μm. (D) HCC4300-PDX-ORG was treated with vehicle, MRTX849, or bosutinib, as well as combinations, after 7 days of treatment. Cell viability of the organoids was measured by CCK-8. (E) HCC4285-PDX-ORG was treated with vehicle, MRTX849, bosutinib, DGY-06-116, or dasatinib, as well as combinations, after 7 days of treatment. Cell viability of the organoids was measured by CCK-8. (F) 3D synergy map displaying ZIP synergy score between MRTX849 and dasatinib, DGY-06-116, or bosutinib in HCC4300-PDX-ORG. (G) Proposed mechanisms and strategies to overcome MRTX849-induced multidrug resistance. In G12Ci-resistant cells, SRC binding with RAF1 bypasses the inhibition of KRAS-G12C by MRTX849, resulting in JUN activation and subsequent ABCC1 and CCND1 expression, and confers a multidrug-resistant phenotype and uncontrolled cell proliferation. Dasatinib, bosutinib, or DGY-06-116 suppresses the phosphorylation of SRC on Y416 and thus inhibits JUN activation and the expression of ABCC1 and CCND1, preventing or reversing G12Ci-induced multidrug resistance and inducing G1 cell cycle arrest. Statistical analysis was performed using two-way ANOVA (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). n = 3 biologically independent samples unless otherwise specified.
Fig. 9. Effects of MRTX849 and SRC inhibitors in the treatment of KRAS-G12C–mutant patient-derived organoids. (A) Patient-derived organoids HCC4300-PDX-ORG were treated with MRTX849 for 1 or 7 days, and the expression of the indicated proteins was measured. The blots shown are representative of three repeats. (B) Patient-derived organoids HCC4300-PDX-ORG treated with vehicle, MRTX849, dasatinib, or DGY-06-116, as well as combinations, after 7 days of treatment. Cell viability of the organoids was measured by CCK-8. (C) Bright-field microscopy images of HCC4300-PDX-ORG treated with vehicle, MRTX849, or bosutinib, as well as combinations, after 7 days of treatment. Scale bars, 50 μm. (D) HCC4300-PDX-ORG was treated with vehicle, MRTX849, or bosutinib, as well as combinations, after 7 days of treatment. Cell viability of the organoids was measured by CCK-8. (E) HCC4285-PDX-ORG was treated with vehicle, MRTX849, bosutinib, DGY-06-116, or dasatinib, as well as combinations, after 7 days of treatment. Cell viability of the organoids was measured by CCK-8. (F) 3D synergy map displaying ZIP synergy score between MRTX849 and dasatinib, DGY-06-116, or bosutinib in HCC4300-PDX-ORG. (G) Proposed mechanisms and strategies to overcome MRTX849-induced multidrug resistance. In G12Ci-resistant cells, SRC binding with RAF1 bypasses the inhibition of KRAS-G12C by MRTX849, resulting in JUN activation and subsequent ABCC1 and CCND1 expression, and confers a multidrug-resistant phenotype and uncontrolled cell proliferation. Dasatinib, bosutinib, or DGY-06-116 suppresses the phosphorylation of SRC on Y416 and thus inhibits JUN activation and the expression of ABCC1 and CCND1, preventing or reversing G12Ci-induced multidrug resistance and inducing G1 cell cycle arrest. Statistical analysis was performed using two-way ANOVA (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). n = 3 biologically independent samples unless otherwise specified.CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 2 Not valid · 9 Not checked · 131 Own results and interpretations

88 more claims · 2 with their cited sources checked

Create a free account to see all 157 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 37
  • It may state two separate claims as one. 32

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Cited by

See all 26

Metadata

Authors
Song, X., Zhou, Z., Elmezayen, A., Wu, R., Yu, C., Gao, B., Minna, J. D., Westover, K. D., Zeh, H. J., Kroemer, G., Heasley, L. E., Kang, R., & Tang, D.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Harold C. Simmons Comprehensive Cancer Center (US)
  • Inserm (FR)
  • VA Eastern Colorado Health Care System (US)
Corresponding author
  • Song, Xinxin
  • Tang, Daolin
Venue
Science Advances
Published
2024-12-13
Volume
10
Issue
50
Pages
eadq4274-eadq4274
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4405280443
Cited by
26
References
86
Citations by year
2026: 18 · 2025: 8
FWCI
7.50
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01 BX004751)
  • National Cancer Institute (R01CA229275, R01CA244341, R01CA211070, R01CA160417, P50CA070907, U54CA224065, P30CA142543)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
KRAS G12C, adagrasib, Src kinase, multidrug resistance, dasatinib, MRP1, c-Jun, MAPK signaling, covalent KRAS inhibitor, non-small cell lung cancer, pancreatic ductal adenocarcinoma, drug synergy, patient-derived organoids
MeSH terms
Dasatinib, Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), Proto-Oncogene Proteins c-jun, Drug Resistance, Multiple, Drug Resistance, Neoplasm, src-Family Kinases, Xenograft Model Antitumor Assays, ATP-Binding Cassette, Sub-Family C Proteins, Cell Line, Tumor, Protein Kinase Inhibitors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.